We read with interest the report by Piva et al. [1] describing an impaired function of the NADPH oxidase, assessed as the reduction of nitroblue tetrazolium (NBT) after stimulation with phorbol myristate acetate (PMA), in patients with various stages of myelodysplastic syndromes and different chronic myeloproli-ferative disorders. In that paper, the authors concluded that PMAinduced NBT reduction was reduced in a few patients with polycythemia vera (PV) that were investigated. Since our group in a series of studies has come to different conclusions regarding the oxidative burst in polymorphonuclear neutrophil granulocytes (PMN) in PV, we would like to briefly comment on the part of the paper by Piva et al.
production was significantly impaired in PV PMN and monocytes. A less pronounced reduction of fMLP stimulated H2O2 production was also noted in CML [10] . In an effort to elucidate the biochemical basis of the impaired oxidative response to fMLP, detailed studies of the different steps in the stimulus-response coupling were performed. They showed that the amount and affinity of fMLP receptors, as well as fMLP-and PMA-induced activation of phospholi-pase C, measured as the generation of 1,4,5-inositoltrisphosphate and the subsequent rise in intracellular calcium, were normal in PV PMN [9] . On the other hand, the activation of phospholipase D (PLD) was impaired, since the generation of phosphatidylethanol (PET) was significantly reduced after fMLP stimulation, whereas the response to PMA, once again, was normal. The mechanism behind impaired PLD activation is currently under investigation by our group. Thus, a series of studies from our laboratory [7] [8] [9] [10] have shown that PMN from PV patients exhibit an impaired oxidative response measured as CL, NBT reduction, superoxide anion and hydrogen peroxide generation after stimulation with fMLP, whereas PMA stimulation has consistently elicited a normal response. Our results therefore seem to be in conflict with the results published by Piva et al. [1] . However, their microscopic NBT reduction test was performed on whole blood, whereas we have used pure PMN preparations, and as Piva et al. pointed out, interactions between PMN and other blood cells can have influenced their results. Furthermore, only 2 PV patients were studied by the microscopic method. Pure PMN from 4 PV patients were investigated photometrically by Piva et al. and the difference in NADPH oxidase activity in this test was less pronounced, and could conceivably be compatible with our findings of normal PMA-enhanced NADPH oxidase activity, if more patients had been studied. Finally, as stated above, we have also found that the pattern of oxidative response varies greatly within the group of myeloproliferative disorders, which leads us to conclude that statistical calculations regarding oxidative metabolism in PMN should be performed on results obtained in a specific disease entity, and not on a group of patients with various myeloproliferative disorders. The letter of Samuelsson and Palmblad has been helpful in prompting further discussion of our findings, which nonetheless do not appear to contradict their own. The respiratory burst oxidase (NADPH oxidase complex) catalyzes the production of (¾~ by activated phagocytes. This activation depends on multiple signal transduction pathways. Failure to produce (¾-is characteristic of chronic gran-ulomatous disease, an inherited phagocyte function disorder and of other diseases, some hematologic malignancies in particular. When we assessed NADPH oxidase activity by the photometric method, no significant differences were found between findings in polycythemia vera (PV) patients and those in control subjects, whether the polymorphonuclear leukocytes (PMN) were stimulated or not (resting PMN). The only stimulus employed in our published study was phorbol myristate acetate (PMA). The activation of the respiratory burst oxidase by PMA is thought to be mediated through the proteinkinase-C-catalyzed phosphorylation of p4Ιphox and possibly other oxidase subunits [1] , whereas N -formyl -methionyl -leucyl -phenylalanine (fMLP) showed protein-kinase-C-indepen-dent pathways and receptor-mediated activation. In our paper, the first study by Samuelsson et al. [2] was quoted as showing normal burst oxidase activity in PV PMN, assessed by chemiluminescence and in response to PMA stimulation: this finding was in agreement with ours obtained with the photometric method. Moreover, in the same study, those authors found that the oxidative metabolism in PV patients was subnormal only after fMLP stimulation, suggesting the presence of a stimulus-response coupling defect and in a more recent detailed studies on the different biochemical steps performed they demonstrated phospholipase-D-me-diated activation impairment [3] . In our paper, we found that patients with myelodysplastic syndromes (MDS) and those with chronic myeloproliferative disorders (cMPD) had similarly reduced scores when evaluated by microscopic NBT reduction, whereas the photometric method showed a cMPD reduction only in patients susceptible to infection. The photometric method was therefore more specific than the microscopic one, this explaining some apparently contradictory findings. Furthermore, since microscopic NBT reduction was performed in whole blood, the interaction
